InnovAge (INNV) Q3 2026 Earnings Transcript

InnovAge reported third-quarter revenue of $251.9 million, up 15.5% year over year, and adjusted EBITDA of $30.5 million versus $10.8 million a year ago, while raising full-year revenue guidance to $950 million-$975 million and adjusted EBITDA guidance to $85 million-$90 million. Participant census grew 6.9% to about 8,050, and center-level contribution margin expanded 550 basis points to 24.2%, though net loss widened to $29.9 million due largely to a litigation liability. Management flagged a more challenging fiscal 2027 rate backdrop, but highlighted AI-driven efficiency efforts and growth initiatives in existing centers, M&A, and partnerships.

Analysis

The setup is better than the headline growth suggests: INNV is converting rate tailwinds plus tighter utilization control into a material step-up in contribution margin, which means incremental revenue is now dropping through more efficiently than it did a year ago. The underappreciated second-order effect is that in-house pharmacy and lower nursing-facility usage are not just cost savings — they are strategic leverage points that should keep peer comparison favorable even if top-line rate help cools in fiscal 2027.

The real swing factor is not this quarter; it is the next rate cycle. Management is effectively telegraphing that the easy part of the turnaround is done and the business now needs to defend margins with operating discipline, sales execution, and census density if Medicaid growth slows. That implies the stock’s multiple can re-rate higher only if investors believe cost inflation remains contained while management keeps converting fixed overhead into operating leverage — otherwise the litigation-driven G&A spike will remind the market how quickly reported earnings can get masked.

What the market may be missing is that this is becoming less of a pure reimbursement story and more of a capacity-utilization story. If AI-enabled scheduling actually reduces cancellations and transportation waste, INNV can squeeze more gross enrollment out of the same footprint, which is a much more valuable earnings driver than modest rate increases. But that thesis needs proof over the next 2-3 quarters; otherwise, the AI discussion risks being viewed as optionality rather than a nearer-term earnings catalyst.

Key Decisions for Investors

• Go long INNV on a pullback over the next 1-3 weeks; the risk/reward favors owning the name into the September fiscal 2027 guide, with upside if management shows rate/cost offsets remain intact and downside protected by improving cash generation.
• Sell out-of-the-money INNV puts 1-2 quarters out to express a view that the market is overpricing near-term rate headwinds; use strikes below the recent trading range where litigation noise rather than operations is the main downside driver.
• Pair trade: long INNV / short a higher-multiple healthcare services peer with weaker reimbursement visibility over the next 3-6 months; the cleaner margin inflection and cash flow conversion should outperform if the market rewards execution over story stock growth.
• If INNV rallies hard into the next earnings call, consider trimming into strength unless September guidance confirms Medicaid pressure is being offset by census density and operating leverage; the valuation can compress quickly if 2027 rates come in soft.
• Avoid chasing the AI narrative via INNV common stock alone; if available, prefer a staged entry and treat AI as a 6-12 month upside call option, not the core underwriting case.